Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 79

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 79
---
 and cell-extracellular matrix interactions that is overexpressed in various mesenchymal tumors where it promotes tumor metastases

MAA: Marketing Authorization Application

Macau: Macau Special Administrative Region

MacroGenics: MacroGenics, Inc. 

MediLink: MediLink Therapeutics (Suzhou) Co., Ltd.

MG: Myasthenia gravis

MMAE: Microtubule-disrupting agent monomethyl auristatin E

MOFCOM: China’s Ministry of Commerce

mOS: Median overall survival

mPFS: Median progression-free survival

Nasdaq: Nasdaq Global Market

NDA: New Drug Application

NHSA: China’s National Healthcare Security Administration 

Ningbo Bank: Bank of Ningbo Co., Ltd. Suzhou Sub-Branch

Ningbo Bank Agreements: Maximum Credit Contract, Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement between Zai Lab Suzhou and Ningbo Bank, collectively 

NIST: National Institute of Standards and Technology

NMPA: China’s National Medical Products Administration

Nominating and Corporate Governance Committee: The Nominating and Corporate Governance Committee of the Board of Directors

NovoCure: NovoCure Ltd.

Novo Holdings: Novo Holdings A/S

NRDL: China’s National Reimbursement Drug List

NSCLC: Non-small cell lung cancer

NTRK: Neurotrophic tropomyosin-receptor kinase

-99-

NUZYRA (Omadacycline): A novel tetracycline-class antibacterial with both oral and IV formulations that is a broad-spectrum antibiotic

OPTUNE: Tumor Treating Fields (or TTFields) devices marketed under various brand names, including OPTUNE GIO® for GBM

ORR: Overall response rate

OS: Overall survival

Our commercial products / programs: ZEJULA, VYVGART / VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO, collectively

Our securities: Our ADSs and/or ordinary shares, individually or collectively

Ovarian cancer: Epithelial ovarian, fallopian tube, and primary peritoneal cancer, collectively

Paratek: Paratek Bermuda Ltd., a subsidiary of Paratek Pharmaceuticals, Inc.

PANSS: Positive and Negative Syndrome Scale

PARP / PARP Inhibitor: PAR